BackRaphael Pharmaceutical Overview

Raphael Pharmaceutical Accounts Payable

Latest accounts payable for RAPH: $540K.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$539000.00
↑ 13.95% YoYΔ $66000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Raphael Pharmaceutical Accounts Payable History

Loading

Raphael Pharmaceutical vs. peers: Accounts Payable Comparison

Loading

Raphael Pharmaceutical Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Raphael Pharmaceutical (RAPH) FAQ

The latest accounts payable for RAPH is $540K as of June 2026. That compares with $470K in the prior-year period — up 14.0% year over year. Investors often review this figure alongside Raphael Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, RAPH's accounts payable moved from $470K to $540K — a 14.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Raphael Pharmaceutical's operating scale or balance-sheet position.

A accounts payable figure of $540K for RAPH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting RAPH's accounts payable ($540K), review year-over-year change from $470K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.